CD57在前列腺偶发癌、临床显性癌及转移癌中的表达

CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate.

作者信息

Wangerin Holger, Kristiansen Glen, Schlomm Thorsten, Stephan Carsten, Gunia Sven, Zimpfer Annette, Weichert Wilko, Sauter Guido, Erbersdobler Andreas

机构信息

Institute of Pathology, University Medicine Rostock, Strempelstraße 14, 18055 Rostock, Germany.

Institute of Pathology, University of Bonn, Germany.

出版信息

Biomed Res Int. 2014;2014:356427. doi: 10.1155/2014/356427. Epub 2014 May 22.

OBJECTIVES

CD57 is normally found on NK-cells, but little is known about its expression in prostatic tissue.

METHODS

We investigated CD57 expression by immunohistochemistry using tissue microarrays containing 3262 prostate cancers (PCa), lymph node metastases, and benign prostatic tissue. The results were compared with clinical and pathological parameters.

RESULTS

Overall, 87% of PCa showed a moderate or strong expression of CD57. There was no significant difference to corresponding benign prostatic tissue. CD57 was increasingly lost from incidental over clinically manifest cancers to metastases. It correlated significantly with Gleason grade and pT-category, but not with PSA tissue expression. Loss of CD57 expression was an independent risk factor for PSA recurrence after prostatectomy in a multivariate Cox regression analysis. In standard sections, CD57 expression was heterogeneous, especially in large, high-grade PCa.

CONCLUSIONS

There is a peculiar expression of CD57 in PCa and benign prostatic tissue. CD57 loss is associated with tumor dedifferentiation and tumor size. However, the use of this marker for prognostic purposes is hampered by its heterogeneous expression.

目的

CD57通常存在于自然杀伤细胞上，但对其在前列腺组织中的表达了解甚少。

方法

我们使用包含3262例前列腺癌（PCa）、淋巴结转移灶和良性前列腺组织的组织芯片，通过免疫组织化学研究CD57的表达情况。将结果与临床和病理参数进行比较。

结果

总体而言，87%的PCa显示CD57呈中度或强表达。与相应的良性前列腺组织相比无显著差异。从偶然发现的癌症到临床表现明显的癌症再到转移灶，CD57表达逐渐丧失。它与Gleason分级和pT分期显著相关，但与PSA组织表达无关。在多变量Cox回归分析中，CD57表达缺失是前列腺切除术后PSA复发的独立危险因素。在标准切片中，CD57表达具有异质性，尤其是在体积大、高级别的PCa中。